Podiatrist Sentenced for $4M Foot Bath Fraud Scheme

Source: United States Department of Justice Criminal Division

A Tennessee podiatrist was sentenced today to four years in prison for a scheme to defraud Medicare and TennCare, a Medicaid program administered by the State of Tennessee, by prescribing and dispensing medically unnecessary foot bath medications and obtaining millions of dollars in reimbursements.

According to court documents and evidence presented at trial, Nathan Lucas, D.P.M., 59, of Memphis, owned and operated a podiatry clinic and two pharmacies. Lucas regularly prescribed antibiotic and antifungal drugs to be mixed into a tub of water for patients to soak their feet. These drug cocktails included capsules, creams, and powders that were not indicated to be dissolved in water and some of which were not even water soluble. Lucas chose these medications to prescribe and dispense based on their anticipated reimbursement amount, rather than medical necessity. From October 2018 through September 2021, Lucas caused his pharmacies to submit nearly $4 million in claims to Medicare and TennCare for dispensing expensive foot bath medications that were not medically necessary and not eligible for reimbursement, for which Lucas’s pharmacies were reimbursed over $3 million.

A federal jury convicted Lucas on March 18 of five counts of health care fraud.

Principal Deputy Assistant Attorney General Nicole M. Argentieri, head of the Justice Department’s Criminal Division; U.S. Attorney Kevin G. Ritz for the Western District of Tennessee; Special Agent in Charge Tamala E. Miles of the Department of Health and Human Services Office of Inspector General (HHS-OIG); and Director David Rausch of the Tennessee Bureau of Investigation (TBI) made the announcement.

HHS-OIG and TBI investigated the case.

Trial Attorney Sara E. Porter and Assistant Chief Justin M. Woodard of the Criminal Division’s Fraud Section prosecuted the case, with assistance from the U.S. Attorney’s Office for the Western District of Tennessee.

The Fraud Section leads the Criminal Division’s efforts to combat health care fraud through the Health Care Fraud Strike Force Program. Since March 2007, this program, currently comprised of nine strike forces operating in 27 federal districts, has charged more than 5,400 defendants who collectively have billed federal health care programs and private insurers more than $27 billion. In addition, the Centers for Medicare & Medicaid Services, working in conjunction with HHS-OIG, are taking steps to hold providers accountable for their involvement in health care fraud schemes. More information can be found at www.justice.gov/criminal-fraud/health-care-fraud-unit.

OVW Fiscal Year 2024 Campus Program Pre-Application Information Session

Source: United States Department of Justice Criminal Division

OVW conducted a live web-based pre-application information session for its Fiscal Year 2024 Grants to Reduce Domestic Violence, Dating Violence, Sexual Assault and Stalking on Campus Program solicitation. During the presentation, OVW staff reviewed this program’s requirements, discussed the solicitation, and allowed for a brief question-and-answer period.

OptumRx Agrees to Pay $20M to Resolve Allegations that It Filled Certain Opioid Prescriptions in Violation of the Controlled Substances Act

Source: United States Department of Justice Criminal Division

OptumRx Inc., a prescription drug benefit provider, has agreed to pay $20 million to resolve allegations that it improperly filled certain opioid prescriptions in violation of the Controlled Substances Act.

The settlement resolves an investigation initiated by the Drug Enforcement Administration (DEA) into whether, between April 2013 and April 2015, OptumRx improperly filled certain opioid prescriptions in combination with other drugs such as benzodiazepines and muscle relaxants, commonly referred to as “trinity” prescriptions. The United States alleged that these combination prescriptions, which OptumRx filled primarily from a mail order pharmacy location in Carlsbad, California, raised “red flags” indicating that the prescriptions may not have been intended for legitimate medical use and could lead to abuse or diversion of highly addictive and powerful opioids. The United States also contended that these trinity prescriptions carry significant risk of harm and that these red flags must be resolved prior to filling a controlled substance prescription. During the course of its investigation, the government alleged that OptumRx received numerous trinity prescriptions that raised red flags but filled those prescriptions without always resolving the red flags.

OptumRx reports that the company has instituted enhanced protocols in handing opioid prescriptions since 2017 to reduce the number, dose and duration of opioid prescriptions it dispenses. OptumRx also reports that it instituted more robust concurrent drug utilization review procedures to assist in identifying and not filling prescriptions for dangerous opioid combinations and excess dosing. During the course of the government’s investigation, OptumRx also closed its mail order pharmacy operations in Carlsbad, California.

“Pharmacies providing opioids and other controlled substances have a duty under the Controlled Substances Act to ensure that they fill prescriptions only for legitimate medical purposes,” said Principal Deputy Attorney General Brian M. Boynton, head of the Justice Department’s Civil Division. “The department will continue to work with its law enforcement partners to ensure that pharmacies do not contribute to the opioid addiction crisis.” 

“Pharmacies are the last line of defense protecting the public from potentially dangerous and addictive medications,” said U.S. Attorney Tara McGrath for Southern District of California. “Combating the opioid crisis on all fronts includes holding pharmacies accountable if they shirk any part of the responsibilities required in filling prescriptions for potentially harmful drugs.”

“DEA registrants have an obligation to protect the public, not help fuel the opioid epidemic,” said Assistant Administrator Thomas W. Prevoznik of  the DEA Diversion Control Division. “The trinity style prescription combination helped fuel the start of the opioid addiction crisis and raises a red flag, which this registrant should have recognized and reacted to rather than putting profits before patients’ safety.”  

DEA’s Office of Diversion Control, San Diego Division Office conducted the investigation.

Assistant U.S. Attorneys Joseph Price, Dylan Aste, Betsy Boutelle and Colin McDonald for the Southern District of California and Trial Attorneys Scott B. Dahlquist and Brandon Robers and Assistant Directors Rachael Doud and Gabriel H. Scannapieco of the Civil Division’s Consumer Protection Branch represented the United States.

This is the second substantial resolution of an opioid related investigation announced by the Justice Department in recent months. Late last year, the department announced a $12 million resolution and consent decree involving Droguería Betances LLC, one of Puerto Rico’s largest drug distributors. In that case, the United States alleged that Betances failed to report to the DEA hundreds of “suspicious orders” for opioids and other controlled substances distributed to Betances’ pharmacy customers.

The claims resolved by the settlement agreement announced today are allegations only. And there has been no determination of liability.

Attorney General Merrick B. Garland Delivers Remarks on a National Health Care Fraud Enforcement Action Resulting in 193 Defendants Charged and Over $2.75 Billion in False Claims

Source: United States Department of Justice Criminal Division

Remarks as Delivered

Good afternoon.

We are here today to announce the results of a two-week nationwide law enforcement action, across 32 federal districts, and against 193 defendants, for their roles in health care fraud schemes.

In addition to the charges and arrests being announced today, we are also announcing that we have seized over $230 million in cash, luxury vehicles, gold, and other assets in connection with these cases.

The Justice Department has been clear that we will bring to justice criminals who defraud Americans and steal from taxpayer-funded programs.

We take a particularly aggressive approach to combating health care fraud schemes that put people in danger for the sake of profits.

Our efforts to combat health care fraud are focused on four fundamental principles:

  • First: protecting vulnerable patients;
  • Second: defending taxpayer-funded programs;
  • Third: ensuring full accountability by prosecuting the perpetrators of these crimes and seizing their criminal proceeds; and
  • Fourth: using data analytics to keep pace with constantly evolving fraud schemes.

First, we are focused on protecting vulnerable patients.

In the Southern District of Florida, we charged three owners of a pharmaceutical wholesale company in a $90 million wire fraud conspiracy to distribute adulterated and misbranded HIV drugs to pharmacies and patients throughout the country.

We allege that the defendants purchased these drugs at steep discounts from black market suppliers and then resold them to pharmacies with falsified documentation designed to conceal the true source of the medication.

As a result, patients at times received bottles labeled as their prescription medication with entirely different drugs inside. One patient passed out and was unconscious for 24 hours after taking an anti-psychotic that he believed was his prescribed HIV medication.

In addition to protecting patients, our approach is guided by our commitment to protecting the taxpayer-funded programs they rely on.

That is why in the District of Arizona, we charged two wound-care company owners and two nurse practitioners in a $900 million Medicare fraud conspiracy targeting elderly patients.

In that case, we allege that the defendants caused unnecessary, highly expensive wound grafts to be applied to elderly Medicare patients — many of whom were terminally ill in hospice care. This was done without coordination with the patients’ treating physicians and without proper treatment for infection.

Medicare paid the defendants more than $1 million per patient for these unnecessary grafts.

The third pillar of our approach is to ensure full accountability for these crimes — not just by charging and arresting those responsible, but also by seizing assets we allege have been stolen from taxpayers.

That is why in the case I just highlighted, we not only charged four defendants, but we also seized tens of millions of dollars in assets — including four luxury vehicles, gold, and bank accounts totaling more than $50 million.

The fourth pillar of our strategy is ensuring that we keep pace with constantly evolving health care fraud schemes. That includes addressing the rise of schemes that exploit telemedicine technology — specifically as it relates to Adderall and other stimulants.

Utilizing proactive data analytics, we identified misuse of telemedicine as a possible source of an increase in prescriptions for stimulants. Thereafter, we worked with law enforcement officers to identify potential schemes. Our investigation led us to a digital health care company called Done.

Earlier this month, we charged and arrested the former CEO and the clinical president of Done for their respective roles in a $100 million scheme to defraud taxpayers and provide easy access to Adderall and other stimulants for no legitimate medical purpose.

Today, we are also announcing that we have charged an additional five defendants for their alleged involvement in that scheme to distribute more than [40 million] medically unnecessary pills.

One of the defendants, who was among the company’s largest prescribers, was indicted for rubber stamping prescriptions without any medical review. As alleged, the defendant also signed prescriptions for patients who were deceased.

I want to be clear: it does not matter if you are a trafficker in a drug cartel or a corporate executive or medical professional employed by a health care company. If you profit from the unlawful distribution of controlled substances, you will be held accountable.

The cases I outlined represent only a fraction of the broader actions that we are announcing today.

Earlier this week, I visited the U.S. Attorney’s Office for the Middle District of Tennessee in Nashville. I spoke with prosecutors who have investigated and charged two defendants with perpetrating a fraud scheme involving millions of dollars in fraudulent Medicare claims and kickback payments. The defendants were arrested on Monday.

This two-week period will be matched with sustained efforts by the Department’s Criminal Division in partnership with our U.S. Attorneys’ Offices nationwide to zero in on health care fraud schemes.

I want to thank the dozens of U.S. Attorneys’ Offices that investigated and prosecuted cases in their districts, the FBI, the DEA, and our partners from across the federal government. And I especially want to recognize the Criminal Division’s Health Care Fraud Unit for their leadership and their excellent work.

We do this work because we know that health care fraud is not a victimless crime.

We will continue to disrupt schemes that target patients at their most vulnerable. We will continue to defend taxpayer-funded programs from fraud. We will continue to bring justice to the perpetrators responsible for these schemes. We will continue to seize the funds they stole from taxpayers.

And as healthcare fraud schemes continue to evolve, so will the Justice Department’s investigative and prosecutorial strategies.

Our messages to those seeking to exploit patients and defraud government programs is clear: you cannot hide your crimes. We will find you, and we will hold you accountable.

Before I close, I want to address today’s Supreme Court order in Moyle v. United States. The Justice Department filed this lawsuit because the Emergency Medical Treatment and Active Labor Act (EMTALA) guarantees essential emergency care to all Americans, no matter which state they live in. If a patient comes into an emergency room with a medical emergency seriously jeopardizing the patient’s life or health, EMTALA requires hospitals to offer the treatment necessary to stabilize that patient, including pregnancy termination, if that is the treatment required to save a woman’s life or prevent serious harm to her health. Today’s order means that, while we continue to litigate our case, women in Idaho will once again have access to the emergency care guaranteed to them under federal law. The Justice Department will continue to use every available tool to ensure that women in every state have access to that care.

And now, I’m going to ask HHS Deputy Secretary Palm, if she would like to say a word.

Virginia Company and Owner Sentenced for Criminally Filling Wetlands

Source: United States Department of Justice Criminal Division

Boyd Farm LLC and its owner Frazier T. Boyd III were sentenced yesterday for criminally filling wetlands in Goochland and Louisa Counties, Virginia. Boyd Farm was sentenced to pay a fine of $300,000 and serve a year of probation for a felony violation of the Clean Water Act. Boyd was sentenced to 30 days home confinement and a year of probation.

At various times between 2017 and 2019, Boyd and his company had workers use excavators and other earthmoving equipment to pull vegetation, grub stumps and grade land at three sites in Virginia’s Piedmont region. The work left behind piles of dirt, slash and stumps. Operators hired by Boyd Farm then placed debris from those piles into wetlands and streams at the properties.

The Clean Water Act requires permits for such discharges into covered wetlands and other waters of the United States. Unpermitted discharges like these can destroy habitat and degrade the pollution cleaning function of wetlands. The United States does issue permits to fill wetlands under some conditions. Boyd Farm and Boyd knew of the requirement for these permits but did not seek or obtain them for any of their properties. In 2015, the Environmental Protection Agency (EPA) had issued Boyd Farm an Administrative Order requiring compliance with the Clean Water Act and requiring restoration of impacted wetlands and streams at another property in Goochland County where unpermitted discharges had occurred.

Assistant Attorney General Todd Kim of the Justice Department’s Environment and Natural Resources Division and U.S. Attorney Jessica D. Aber for the Eastern District of Virginia made the announcement.

EPA’s Criminal Investigation Division investigated the case, with assistance from the Virginia Department of Environmental Quality.

Trial Attorney Elise Kent Bernanke of the Environment and Natural Resources Division and Assistant U.S. Attorney Michael Moore for the Eastern District of Virginia prosecuted the case.